Eli Lilly and Co (LSE:LEL)
$ 56.25 0 (1.24%) Market Cap: 63.81 Bil Enterprise Value: 87.52 Bil PE Ratio: 113.50 PB Ratio: 56.21 GF Score: 81/100

Eli Lilly and Co at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 28, 2021 / 05:20PM GMT
Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Good afternoon. I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Eli Lilly.

Lilly is a leading global pharmaceutical company with robust portfolio of fast-growing products and pipeline of first-in-class and/or best-in-class drugs. We think the company's earnings profile continues to look favorable when compared with those of its peers. Its margin profile represents one of the strongest expansion stories in pharma, with the potential for mid-teens EPS growth.

Lilly is entering a period of earnings and growth unencumbered by large loss of exclusivities and bolstered by multiple pipeline readouts of its first-in-class and best-in-class compounds. Therefore, we're thrilled to have with us today Patrik Jonsson, Senior Vice President of Eli Lilly & Company, President of Lilly Immunology, President of Lilly USA; and Chief Customer Officer, with us here today.

So Patrik, would you like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot